Spots Global Cancer Trial Database for rituxan
Every month we try and update this database with for rituxan cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma | NCT02260804 | Follicular Lymp... | CT-P10 Rituxan | 18 Years - | Celltrion | |
| Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma | NCT01983969 | Advanced Cancer... Lymphoma | Azacitidine Vorinostat Gemcitabine Busulfan Melphalan Dexamethasone Caphosol Glutamine Pyridoxine Rituximab | 15 Years - 65 Years | M.D. Anderson Cancer Center | |
| Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma | NCT02280525 | Leukemia | Lenalidomide Rituximab Fludarabine Cyclophosphamid... NK Cells Cytarabine | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia | NCT00759603 | Chronic Lymphoc... Small Lymphocyt... | Lenalidomide Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma | NCT00081861 | Lymphoma | Avastin Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma | NCT01029730 | Lymphoma | Bendamustine Bortezomib Rituximab | 18 Years - | SCRI Development Innovations, LLC | |
| A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma | NCT02532192 | Lymphoma | Belinostat Rituximab Cisplatin Cytarabine Dexamethasone Ciprofloxacin Fluconazole | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Phase II Trial of Pentostatin and Targeted Busulfan | NCT00496340 | Hematologic Mal... | Pentostatin Busulfan Rituximab Allogeneic Hema... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Cellular Therapy With Cord Blood Cells | NCT00427557 | Multiple Myelom... Leukemia Lymphoma | Fludarabine Melphalan Umbilical Cord ... Rituximab Peripheral Bloo... | - 80 Years | M.D. Anderson Cancer Center | |
| Randomized Double Cord Blood Transplant Study | NCT00067002 | Leukemia, Lymph... Leukemia, Myelo... Leukemia, Myelo... Lymphoma, Non-H... | Expanded alloge... One Unmanipulat... Rituxan Melphalan Thiotepa Fludarabine Cyclophosphamid... Mesna Total body irra... | 1 Month - 80 Years | M.D. Anderson Cancer Center | |
| Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela ) | NCT01569295 | Chronic Lymphoc... | Idelalisib Rituximab Bendamustine Placebo to matc... | 18 Years - | Gilead Sciences | |
| Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL) | NCT00758693 | Chronic Lymphoc... | Bendamustine Rituximab | 65 Years - | University of Kentucky | |
| Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102) | NCT00168740 | Low-Grade or Fo... | rituximab | 18 Years - | Biogen | |
| Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma | NCT00904722 | Lymphoma | CT-011 Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies | NCT01421173 | Lymphoma | Vorinostat Gemcitabine Busulfan Melphalan Stem Cell Infus... Rituximab G-CSF Palifermin Dexamethasone a... | 12 Years - 65 Years | M.D. Anderson Cancer Center | |
| Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention | NCT02423915 | Leukemia Lymphoma | Rituximab Fludarabine Cyclophosphamid... Total Body Radi... Fucosylated Reg... Cord Blood Infu... Mycophenolate m... Sirolimus Bone Marrow Asp... G-CSF Non-Fucosylated... | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Safety and Efficacy of Campath in Nonmyeloablative Transplantation | NCT00038844 | Lymphoma Leukemia | Campath-1 H (Al... Fludarabine Cyclophosphamid... Rituximab | - 70 Years | M.D. Anderson Cancer Center | |
| Cellular Therapy With Cord Blood Cells | NCT00427557 | Multiple Myelom... Leukemia Lymphoma | Fludarabine Melphalan Umbilical Cord ... Rituximab Peripheral Bloo... | - 80 Years | M.D. Anderson Cancer Center | |
| Rituximab and ABVD for Hodgkin's Patients | NCT00504504 | Lymphoma | Rituximab Adriamycin Bleomycin Vinblastine Dacarbazine (DT... | 16 Years - | M.D. Anderson Cancer Center | |
| Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma | NCT01889797 | Indolent Non-Ho... | Arm A: Rituxima... Arm B: GA101 | 18 Years - | PrECOG, LLC. | |
| Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma | NCT02280525 | Leukemia | Lenalidomide Rituximab Fludarabine Cyclophosphamid... NK Cells Cytarabine | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma | NCT00556699 | Non-Hodgkin's L... | rituximab SGN-40 | 18 Years - | Genentech, Inc. | |
| Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma | NCT00387023 | Non-Hodgkin's L... Lymphoma | Rituximab Zevalin | 18 Years - | M.D. Anderson Cancer Center | |
| Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | NCT01082939 | Chronic Lymphoc... | Fludarabine Cyclophosphamid... Alemtuzumab Rituximab | - | M.D. Anderson Cancer Center | |
| Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23) | NCT01253460 | Leukemia | Cyclophosphamid... Rituximab Sapacitabine | 18 Years - | M.D. Anderson Cancer Center | |
| Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | NCT01647971 | Non-Hodgkins Ly... B-cell Lymphoma Waldenstrom's M... Marginal Zone L... Chronic Lymphoc... Small Lymphocyt... Primary Central... | Ublituximab | 18 Years - | TG Therapeutics, Inc. | |
| Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies | NCT00048737 | Lymphoma Leukemia | Zevalin Radioim... Rituximab Fludarabine Cyclophosphamid... Allogeneic Stem... | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL) | NCT01134575 | Acute Lymphobla... | CMC-544 (Inotuz... Rituximab | 16 Years - | M.D. Anderson Cancer Center | |
| Rituximab and ABVD for Hodgkin's Patients | NCT00504504 | Lymphoma | Rituximab Adriamycin Bleomycin Vinblastine Dacarbazine (DT... | 16 Years - | M.D. Anderson Cancer Center | |
| Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) | NCT00628238 | Chronic Lymphoc... CLL Untreated Front-line First-Line Initial Therapy | Lenalidomide an... Lenalidomide an... | - | Chronic Lymphocytic Leukemia Research Consortium | |
| Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102) | NCT00168740 | Low-Grade or Fo... | rituximab | 18 Years - | Biogen | |
| Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies | NCT01471067 | Blood And Marro... Leukemia Lymphoma Transplantation... Transplantation... | Melphalan Fludarabine Mycophenolate m... Tacrolimus Cord Blood Infu... Rituximab ATG Busulfan Clofarabine Total Body Irra... | 1 Year - 80 Years | M.D. Anderson Cancer Center | |
| Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma | NCT01234467 | Diffuse Large B... Lymphoma, Diffu... Diffuse Large-C... Lymphoma | Bendamustine Rituximab | 65 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma | NCT00440388 | Follicular Lymp... | AT-101 Rituximab | 18 Years - | Ascenta Therapeutics | |
| Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma | NCT00411086 | Lymphoma | Rituximab Sargramostim (G... | 18 Years - | M.D. Anderson Cancer Center | |
| Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia | NCT01125293 | Waldenstrom's M... | Everolimus Rituximab Bortezomib | 18 Years - | Dana-Farber Cancer Institute | |
| A Pilot Trial of Rituxan in Refractory Myasthenia Gravis | NCT00619671 | Refractory Myas... | Rituximab (Ritu... | 18 Years - 80 Years | University of Vermont | |
| FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years | NCT00254410 | Chronic Lymphoc... | Fludarabine Cyclophosphamid... Mitoxantrone Rituximab Filgrastim | - 70 Years | M.D. Anderson Cancer Center | |
| Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies | NCT00472056 | Lymphoma | Carmustine Etoposide Cytarabine Melphalan Rituximab | - 80 Years | M.D. Anderson Cancer Center | |
| Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) | NCT00628238 | Chronic Lymphoc... CLL Untreated Front-line First-Line Initial Therapy | Lenalidomide an... Lenalidomide an... | - | Chronic Lymphocytic Leukemia Research Consortium | |
| Rituximab + GM-CSF in Patients With Follicular B-Cell Lymphoma | NCT01939730 | Lymphoma | Rituximab GM-CSF | 18 Years - | M.D. Anderson Cancer Center | |
| SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL) | NCT00076349 | Non-Hodgkin's L... | bendamustine an... | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma | NCT01900496 | Lymphoma | Brentuximab ved... Rituximab | 16 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation | NCT00591630 | Diffuse Large C... Lymphoma | Zevalin Carmustine Etoposide Cytarabine Melphalan Rituximab Stem Cell Trans... | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL) | NCT01096992 | Leukemia | Bendamustine Fludarabine Rituximab | 16 Years - | M.D. Anderson Cancer Center | |
| Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen | NCT00074165 | Brain and Centr... Drug/Agent Toxi... Lymphoma Thrombocytopeni... | Rituxan Cyclophosphamid... Etoposide Etoposide phosp... Carboplatin Sodium thiosulf... Neupogen Neulasta Cytarabine | 18 Months - 75 Years | OHSU Knight Cancer Institute | |
| Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma | NCT01729104 | Lymphoma | Carfilzomib Lenalidomide Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Rituximab and ABVD for Hodgkin's Patients | NCT00504504 | Lymphoma | Rituximab Adriamycin Bleomycin Vinblastine Dacarbazine (DT... | 16 Years - | M.D. Anderson Cancer Center | |
| Safety and Efficacy of Campath in Nonmyeloablative Transplantation | NCT00038844 | Lymphoma Leukemia | Campath-1 H (Al... Fludarabine Cyclophosphamid... Rituximab | - 70 Years | M.D. Anderson Cancer Center | |
| Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease | NCT01702961 | Lymphoma Hodgkin's Disea... | Melphalan Ara-C VP-16 BCNU Rituxan Stem Cells | - | Baylor College of Medicine | |
| Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention | NCT02423915 | Leukemia Lymphoma | Rituximab Fludarabine Cyclophosphamid... Total Body Radi... Fucosylated Reg... Cord Blood Infu... Mycophenolate m... Sirolimus Bone Marrow Asp... G-CSF Non-Fucosylated... | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL) | NCT01134575 | Acute Lymphobla... | CMC-544 (Inotuz... Rituximab | 16 Years - | M.D. Anderson Cancer Center | |
| Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma | NCT00081861 | Lymphoma | Avastin Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies | NCT01871675 | Lymphoma Chronic Lymphoc... Non-Hodgkin Lym... T-cell Lymphoma | IPI-145 Rituximab Bendamustine | 18 Years - | SCRI Development Innovations, LLC | |
| Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma | NCT00251394 | Non-Hodgkin's L... | Rituxan 1018 ISS | 18 Years - | Dana-Farber Cancer Institute | |
| Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma | NCT00294632 | Lymphoma | Lenalidomide Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma | NCT01538472 | Lymphoma | Y Zevalin In Zevalin Rituxan BCNU VP -16 Ara-C Melphalan Stem Cell Infus... G-CSF | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan | NCT02162771 | Lymphoma, Folli... | Rituxan CT-P10 Cyclophosphamid... Vincristine Prednisone | 18 Years - | Celltrion | |
| Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma | NCT00411086 | Lymphoma | Rituximab Sargramostim (G... | 18 Years - | M.D. Anderson Cancer Center | |
| Phase II Trial of Pentostatin and Targeted Busulfan | NCT00496340 | Hematologic Mal... | Pentostatin Busulfan Rituximab Allogeneic Hema... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma | NCT00060684 | Lymphoma, Low-G... Lymphoma, Small... Lymphoma, Mixed... Lymphoma, Small... | Pixantrone (BBR... fludarabine dexamethasone rituximab | 18 Years - | CTI BioPharma | |
| Study of Bortezomib in Combination With Cyclophosphamide and Rituximab | NCT00958256 | Mantle Cell Lym... Lymphoma | Bortezomib Rituximab Cyclophosphamid... Mesna G-CSF | 18 Years - 85 Years | M.D. Anderson Cancer Center | |
| Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma | NCT01538472 | Lymphoma | Y Zevalin In Zevalin Rituxan BCNU VP -16 Ara-C Melphalan Stem Cell Infus... G-CSF | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma | NCT01234467 | Diffuse Large B... Lymphoma, Diffu... Diffuse Large-C... Lymphoma | Bendamustine Rituximab | 65 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma | NCT01900496 | Lymphoma | Brentuximab ved... Rituximab | 16 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela ) | NCT01569295 | Chronic Lymphoc... | Idelalisib Rituximab Bendamustine Placebo to matc... | 18 Years - | Gilead Sciences | |
| Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL) | NCT01096992 | Leukemia | Bendamustine Fludarabine Rituximab | 16 Years - | M.D. Anderson Cancer Center | |
| Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL | NCT00089284 | Non-Hodgkin's L... | Rituxan motexafin gadol... 111Indium-Zeval... | 18 Years - | Northwestern University | |
| Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant | NCT01321541 | Diffuse Large B... de Novo DLBCL DLBCL Transform... Follicular Grad... | Pixantrone + Ri... Gemcitabine + R... | 18 Years - | CTI BioPharma | |
| Rituximab Maintenance After Autologous Transplantation | NCT01103388 | Non-Hodgkin's L... | Rituximab | - | M.D. Anderson Cancer Center | |
| Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma | NCT01234467 | Diffuse Large B... Lymphoma, Diffu... Diffuse Large-C... Lymphoma | Bendamustine Rituximab | 65 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL | NCT00452374 | Leukemia | Cytarabine Fludarabine Oxaliplatin Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma | NCT01029730 | Lymphoma | Bendamustine Bortezomib Rituximab | 18 Years - | SCRI Development Innovations, LLC | |
| Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma | NCT00901927 | Follicular Lymp... | Bendamustine Mitoxantrone Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia | NCT03531736 | Myeloid Disease... | Antithymocyte g... fludarabine total body irra... cyclophosphamid... Rituxan Allogeneic Hema... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies | NCT00473551 | Leukemia Lymphoma Myeloma | Rituximab Cyclophosphamid... Fludarabine Mesna Radiation Treat... Stem Cell Trans... Sirolimus Anti-third Part... | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma | NCT00290511 | Lymphoma | Fludarabine Mitoxantrone Rituximab Zevalin Dexamethasone | 60 Years - | M.D. Anderson Cancer Center | |
| Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma | NCT01729104 | Lymphoma | Carfilzomib Lenalidomide Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia | NCT02165397 | Waldenström's M... | Ibrutinib Placebo Rituximab | 18 Years - | Pharmacyclics LLC. | |
| Phase II Trial of Pentostatin and Targeted Busulfan | NCT00496340 | Hematologic Mal... | Pentostatin Busulfan Rituximab Allogeneic Hema... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
